Allogene Therapeutics, Inc.

ALLO

$2.00

+0.76%

2026-09-04 10:31:17 EDT+$0.02

Healthcare

Biotechnology

NASDAQ

Active Trading

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for ...

Price Action of ALLO

$2.00

+0.76%+$0.02

High—

Low—

52W High-55.2%

Rel. vol—

Interval

Range61m

Volume—SMA5SMA10

—

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company headquartered in South San Francisco, California, dedicated to creating and commercializing genetically engineered allogeneic T-cell therapies for the treatment of various cancers. The company's lead product candidate, UCART19, is an allogeneic chimeric antigen receptor (CAR) T-cell therapy being developed for relapsed/refractory (R/R) ...Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company headquartered in South San Francisco, California, dedicated to creating and commercializing genetically engineered allogeneic T-cell therapies for the treatment of various cancers. The company's lead product candidate, UCART19, is an allogeneic chimeric antigen receptor (CAR) T-cell therapy being developed for relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. Its pipeline also includes ALLO-501 and ALLO-501A, anti-CD19 allogeneic CAR T-cell candidates in clinical trials for non-Hodgkin lymphoma and large B-cell lymphoma, respectively. Additionally, the company is advancing ALLO-715 and ALLO-605 for multiple myeloma, ALLO-647 (an anti-CD52 monoclonal antibody), and other preclinical candidates targeting CD70, ALLO-819 for acute myeloid leukemia, and DLL3 for small cell lung cancer. Allogene has established strategic partnerships with Pfizer, Servier, Cellectis, Notch Therapeutics, and SpringWorks Therapeutics, as well as a collaboration with MD Anderson Cancer Center. Financially, the company has a market cap of approximately $694 million, with a negative net income and no revenue, reflecting its clinical-stage status. It employs around 150 people, and its leadership includes CEO Zachary Roberts, with co-founder David Chang transitioning to a board role. The company's focus is on making CAR T-cell therapy more accessible and convenient by using healthy donor cells, aiming to overcome the limitations of autologous therapies.ExpandCollapse

Founded

2017

Employees

151

CEO

Zachary Roberts

Full Name

Allogene Therapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-50.04%

Market Cap

$0.69B

Current Ratio

10.72

WACC

6.37%

ROIC

-39.72%

Contact Information

https://www.allogene.com

650 457 2700

210 East Grand Avenue, South San Francisco, CA 94080

Key Metrics of ALLO

Snapshot

Latest / TTM · 6 periods

Market Cap

$689.25M

ROCE

-34.8%

EV / EBITDA

-4.72x

+19.2% YoY

FCF Yield

-14.9%

+34.6% YoY

Cash Conversion Cycle

-58.7d

Current Ratio

10.72

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of ALLO

Profitability trend

Latest / TTM · 6 periods

Gross Margin

-699.4%

Net Margin

-3566.7%

P/E Ratio

-2.98x

n/a

Debt / Equity

0.16

n/a

Current Ratio

10.72

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of ALLO

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.15 · Revenue $2500.00 · 6 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.15 · Revenue $2500.00 · 6 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.60 · Revenue $3.82M · 8 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.15 · Revenue $5000.00 · 2 analysts

Recent history

Aug 12, 2026
Q2 FY2026 · Results reported
EPS $-0.13 · Revenue $4.64M
View filing
May 13, 2026
Q1 FY2026 · Results reported
EPS $-0.18 · Revenue $0.00
View filing
Mar 12, 2026
FY2025 · Annual results
EPS $-0.87 · Revenue $0.00
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $-0.19 · Revenue $0.00
View filing
Aug 13, 2025
Q2 FY2025 · Results reported
EPS $-0.23 · Revenue $0.00
View filing
May 13, 2025
Q1 FY2025 · Results reported
EPS $-0.28 · Revenue $0.00
View filing

Financial Statements of ALLO

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	-100.0%	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-190.9M	+25.9%	-0.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-149.6M	+25.6%	-148.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	28.5%	+32.4%	-44.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	7.93x	-7.2%	+11.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$415.9M	-24.2%	+38.9%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.87 vs -0.93	+6.1%	-0.13 vs -0.17	+24.1%
Revenue Surprise	$0 vs $1667	-100.0%	$4.6M vs $2500	+185500.0%

Insider Transactions of ALLO

Acquisitions (A)

Since Jun 18, 2026

Disposals (D)

Since Jun 18, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 21, 2026	Douglas Earl Martin	officer: SVP, General Counsel	Common Stock	D	29,697	$2.12
Jul 1, 2026	Roberts Zachary	officer: President and CEO	Stock Option (Right to buy)	A	476,190	$2.11
Jul 1, 2026	Roberts Zachary	officer: President and CEO	Restricted Stock Unit	A	134,530	—
Jun 18, 2026	Kazam Joshua A	director	Common Stock	A	47,700	—
Jun 18, 2026	Kazam Joshua A	director	Restricted Stock Unit	A	95,400	—

Earnings Call Transcript of ALLO

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Hello. Thank you for standing by and welcome to Allogene Therapeutics second quarter 2026 conference call. [Operator Instructions] Please be aware that today's conference call is being recorded. I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead. Christine Cassiano: Thank you, Operator, and welcome everyone to Allogene's conference call. After the market closed, Allogene issued a press release that provided a business update and financial results for the second quarter of 2026. This press release and today's webcast are available on our website. Following brief prepared remarks from Dr. Zachary Roberts, President and Chief Executive Officer, we will open the call for questions. Geoff Parker, Chief Financial Officer, will also join the Q&A. To help us conclude within 45 minutes, we ask that each analyst limit themselves to one question. During today's call, we will be making certain forward-looking statements These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, commercial market forecasts, the potential treatment setting, and financial guidance, among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of potential risks can be found in our press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements. I'm going to turn the call over to Zach. Zachary Roberts: Thanks, Christine, and good afternoon, everyone. This is my first quarterly call as CEO, and it marks the beginning of a new chapter for Allogene, one made possible by the foundation David Chang helped build. David has been my mentor and one of the people who has most shaped how I think about cell therapy and drug development. More than that, he co-founded and built this company, led the field in the generation of clinical data in patients with relapsed cancer, and created the framework we needed to take Allogene into its next chapter. When I joined Allogene, my mandate was clear. Challenge the conventional thinking about how allogeneic CAR-T should be developed. That meant starting with the patient and working backward. Understand what patients and their care teams need, then design products and clinical programs that meet those needs. That work led to a deliberate strategic shift announced in 2024, designing programs and products that leverages features of the allogeneic cell therapy into a clinical advantage. We focused on settings that demand the unique attributes of off-the-shelf CAR T, ready availability, consistent product quality that is …

Leadership Team of ALLO

10 executives

Name	Title	Compensation	Gender	Year Born	Status
David D. Chang	Co-Founder & Director	USD 1,138,227	—	1960	Active
Joshua A. Kazam	Co-Founder & Director	USD 1,138,227	Male	1977	Active
Zachary J. Roberts	President, CEO & Director	USD 750,761	—	1978	Active
Arie S. Belldegrun	Co-Founder & Executive Chairman	USD 728,726	—	1949	Active
Geoffrey Parker	Executive Vice President & Chief Financial Officer	USD 707,000	Male	1965	Active
Christine Cassiano	Executive Vice President, Chief Corporate Affairs & Brand Strategy Officer	—	Female	—	Active
Susan R. Lundeen	Chief People Officer	—	Female	1966	Active
Earl Douglas	Senior Vice President, General Counsel, Compliance Officer & Corporate Secretary	—	Male	1963	Active
Benjamin Beneski	Senior Vice President & Chief Technical Officer	—	Male	1977	Active
Annie Yoshiyama	SVP & Corporate Controller	—	Female	1984	Active

Recent News of ALLO

Zacks Investment Research8/13/2026Neutral

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.

Defense World8/13/2026Neutral

Allogene Therapeutics, Inc. $ALLO Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 25.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,201,655 shares of the company's stock after acquiring an additional 243,839 shares during the quarter. Dimensional Fund Advisors

Seeking Alpha8/12/2026Neutral

Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript

MarketBeat8/12/2026Neutral

Allogene Therapeutics Q2 Earnings Call Highlights

Allogene Therapeutics NASDAQ: ALLO outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3 lymphoma study, recent FDA designations for cema-cel, published renal cell carcinoma data for ALLO-316, and plans to report initial data from the ALLO-329 autoimmune program by year-end.

GlobeNewsWire8/12/2026Neutral

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended June 30, 2026.

Historical Employee Count of ALLO

Current

150

Change

-33.63%

Minimum

150

Maximum

359

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	150	10-K	Mar 12, 2026	View
Dec 31, 2024	226	10-K	Mar 13, 2025	View
Dec 31, 2023	232	10-K	Mar 14, 2024	View
Dec 31, 2022	359	10-K	Feb 28, 2023	View
Dec 31, 2021	308	10-K	Feb 23, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Allogene Therapeutics, Inc.